Loading…

Cadherin 5 and Annexin V as Circulating Endothelial Microparticles: Markers for Atherosclerotic Vascular Lesions in Patients with Chronic Renal Failure

Cardiovascular disease is the leading cause of death in Chronic kidney disease patients. This study tries to identify circulating endothelial microparticles {MPs} [such as Cadherin 5 and Anexin V] in CKD patients with and without IHD as potential new risk factors of atherosclerotic vascular disease....

Full description

Saved in:
Bibliographic Details
Published in:Kidney (Springer International (Firm)) 2010, Vol.19 (6), p.307-315
Main Authors: Shehata, Mohammed, El Abd, Dina, El Shanawani, Faten, Abdallah, Emad Ali, Darwish, Hesham, Moghazy, Mahmoud Farok, Metwaly, Amna, Hadi, Afaf Ahmed Abdel
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c1090-5e13da46489383cb04ea5931872bc43b76b0aa4662079080d3549d6691e6df853
container_end_page 315
container_issue 6
container_start_page 307
container_title Kidney (Springer International (Firm))
container_volume 19
creator Shehata, Mohammed
El Abd, Dina
El Shanawani, Faten
Abdallah, Emad Ali
Darwish, Hesham
Moghazy, Mahmoud Farok
Metwaly, Amna
Hadi, Afaf Ahmed Abdel
description Cardiovascular disease is the leading cause of death in Chronic kidney disease patients. This study tries to identify circulating endothelial microparticles {MPs} [such as Cadherin 5 and Anexin V] in CKD patients with and without IHD as potential new risk factors of atherosclerotic vascular disease. This study was carried out in Theodor Bilharz Research Institute [TBRI] on 60 patients with chronic kidney disease on maintenance hemodialysis. They were 41 male and 19 females selected from hemodialysis unit in TBRI. They were further subclassified into the following two groups according to the Echocardiography and Electrocardiogram (ECG) to 25 patients of chronic kidney disease without cardiac complications (17 males, 8 females and ages were 53.5 ± 9.9 years) and 35 patients of chronic kidney disease with cardiac complications (24 males, 11 females and ages were 57.5 ± 7.4 years). Twenty healthy subjects were selected as healthy control, their age 50 ± 9 years. Cadherin 5 & Annexin V Were done by enzyme linked immunosorbant assay (ELISA). The mean cadherin 5 levels in CKD with ischemic HD, CKD without ischemic HD and control group were 86.99 ± 21.51, 33.21 ± 8.65 and 2.63 ± 1.47 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p < 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p < 0.01). As regard to the mean annexin v levels in CKD with ischemic HD, CKD without ischemic HD and control group were 83.73 ± 22.64, 28.51 ± 9.73 and 0.47 ± 0.36 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p < 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p < 0.01). Endothelial dysfunction leading to atherosclerotic vascular disease in patients with CKD can be assessed quantitatively by measurement of plasma levels of endothelial microparticles such as CD144-EMP (Cadherin 5) and Annexin V.
doi_str_mv 10.1007/s00596-010-0176-0
format article
fullrecord <record><control><sourceid>fao_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_s00596_010_0176_0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US201301922286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1090-5e13da46489383cb04ea5931872bc43b76b0aa4662079080d3549d6691e6df853</originalsourceid><addsrcrecordid>eNp9kNFO3DAQRS1UpG6hH9An_AOh4zh2bN5WEVCkRUWl8Gp5E2fXEGw0kxXlS_q79Wp57oM1tu69R57L2DcB5wKg_U4AyuoKBJTTlssRWwijVaVAm09sAbaBqrVSf2ZfiJ4AwLRKL9jfzg_bgDFxxX0a-DKl8Ke8Hrkn3kXsd5OfY9rwyzTkeRum6Cd-G3vMrx7n2E-BLvitx-eAxMeMfFlMmKkImIvOHz3tGchXgWJOxAv8riBDmom_xXnLuy3mVJy_QirsKx-nHYZTdjz6icLXj3nCHq4uf3c_qtXP65tuuap6ARYqFYQcfKMbY6WR_Rqa4JWVwrT1um_kutVr8EXXNbQWDAxSNXbQ2oqgh9EoecLEgVs2IsIwuleMLx7fnQC3b9YdmnWlWbdv1kHJ1IcMFW_aBHRPeYfl8_Tf0NkhNPrs_AYjuYf7GoQEYeu6Nlr-A3i2hhE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Cadherin 5 and Annexin V as Circulating Endothelial Microparticles: Markers for Atherosclerotic Vascular Lesions in Patients with Chronic Renal Failure</title><source>Alma/SFX Local Collection</source><creator>Shehata, Mohammed ; El Abd, Dina ; El Shanawani, Faten ; Abdallah, Emad Ali ; Darwish, Hesham ; Moghazy, Mahmoud Farok ; Metwaly, Amna ; Hadi, Afaf Ahmed Abdel</creator><creatorcontrib>Shehata, Mohammed ; El Abd, Dina ; El Shanawani, Faten ; Abdallah, Emad Ali ; Darwish, Hesham ; Moghazy, Mahmoud Farok ; Metwaly, Amna ; Hadi, Afaf Ahmed Abdel</creatorcontrib><description>Cardiovascular disease is the leading cause of death in Chronic kidney disease patients. This study tries to identify circulating endothelial microparticles {MPs} [such as Cadherin 5 and Anexin V] in CKD patients with and without IHD as potential new risk factors of atherosclerotic vascular disease. This study was carried out in Theodor Bilharz Research Institute [TBRI] on 60 patients with chronic kidney disease on maintenance hemodialysis. They were 41 male and 19 females selected from hemodialysis unit in TBRI. They were further subclassified into the following two groups according to the Echocardiography and Electrocardiogram (ECG) to 25 patients of chronic kidney disease without cardiac complications (17 males, 8 females and ages were 53.5 ± 9.9 years) and 35 patients of chronic kidney disease with cardiac complications (24 males, 11 females and ages were 57.5 ± 7.4 years). Twenty healthy subjects were selected as healthy control, their age 50 ± 9 years. Cadherin 5 &amp; Annexin V Were done by enzyme linked immunosorbant assay (ELISA). The mean cadherin 5 levels in CKD with ischemic HD, CKD without ischemic HD and control group were 86.99 ± 21.51, 33.21 ± 8.65 and 2.63 ± 1.47 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p &lt; 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p &lt; 0.01). As regard to the mean annexin v levels in CKD with ischemic HD, CKD without ischemic HD and control group were 83.73 ± 22.64, 28.51 ± 9.73 and 0.47 ± 0.36 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p &lt; 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p &lt; 0.01). Endothelial dysfunction leading to atherosclerotic vascular disease in patients with CKD can be assessed quantitatively by measurement of plasma levels of endothelial microparticles such as CD144-EMP (Cadherin 5) and Annexin V.</description><identifier>ISSN: 0940-7936</identifier><identifier>EISSN: 1865-5068</identifier><identifier>DOI: 10.1007/s00596-010-0176-0</identifier><language>eng</language><publisher>New York: New York : Springer-Verlag</publisher><subject>Annexin V ; Cadherin5 ; CKD ; Endothelial dysfunction ; Haemodialysis ; Medicine ; Medicine &amp; Public Health ; myocardial ischemia ; Nephrology ; Urology</subject><ispartof>Kidney (Springer International (Firm)), 2010, Vol.19 (6), p.307-315</ispartof><rights>Springer Science+Business Media, LLC 2010</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1090-5e13da46489383cb04ea5931872bc43b76b0aa4662079080d3549d6691e6df853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Shehata, Mohammed</creatorcontrib><creatorcontrib>El Abd, Dina</creatorcontrib><creatorcontrib>El Shanawani, Faten</creatorcontrib><creatorcontrib>Abdallah, Emad Ali</creatorcontrib><creatorcontrib>Darwish, Hesham</creatorcontrib><creatorcontrib>Moghazy, Mahmoud Farok</creatorcontrib><creatorcontrib>Metwaly, Amna</creatorcontrib><creatorcontrib>Hadi, Afaf Ahmed Abdel</creatorcontrib><title>Cadherin 5 and Annexin V as Circulating Endothelial Microparticles: Markers for Atherosclerotic Vascular Lesions in Patients with Chronic Renal Failure</title><title>Kidney (Springer International (Firm))</title><addtitle>Kidney</addtitle><description>Cardiovascular disease is the leading cause of death in Chronic kidney disease patients. This study tries to identify circulating endothelial microparticles {MPs} [such as Cadherin 5 and Anexin V] in CKD patients with and without IHD as potential new risk factors of atherosclerotic vascular disease. This study was carried out in Theodor Bilharz Research Institute [TBRI] on 60 patients with chronic kidney disease on maintenance hemodialysis. They were 41 male and 19 females selected from hemodialysis unit in TBRI. They were further subclassified into the following two groups according to the Echocardiography and Electrocardiogram (ECG) to 25 patients of chronic kidney disease without cardiac complications (17 males, 8 females and ages were 53.5 ± 9.9 years) and 35 patients of chronic kidney disease with cardiac complications (24 males, 11 females and ages were 57.5 ± 7.4 years). Twenty healthy subjects were selected as healthy control, their age 50 ± 9 years. Cadherin 5 &amp; Annexin V Were done by enzyme linked immunosorbant assay (ELISA). The mean cadherin 5 levels in CKD with ischemic HD, CKD without ischemic HD and control group were 86.99 ± 21.51, 33.21 ± 8.65 and 2.63 ± 1.47 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p &lt; 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p &lt; 0.01). As regard to the mean annexin v levels in CKD with ischemic HD, CKD without ischemic HD and control group were 83.73 ± 22.64, 28.51 ± 9.73 and 0.47 ± 0.36 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p &lt; 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p &lt; 0.01). Endothelial dysfunction leading to atherosclerotic vascular disease in patients with CKD can be assessed quantitatively by measurement of plasma levels of endothelial microparticles such as CD144-EMP (Cadherin 5) and Annexin V.</description><subject>Annexin V</subject><subject>Cadherin5</subject><subject>CKD</subject><subject>Endothelial dysfunction</subject><subject>Haemodialysis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>myocardial ischemia</subject><subject>Nephrology</subject><subject>Urology</subject><issn>0940-7936</issn><issn>1865-5068</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9kNFO3DAQRS1UpG6hH9An_AOh4zh2bN5WEVCkRUWl8Gp5E2fXEGw0kxXlS_q79Wp57oM1tu69R57L2DcB5wKg_U4AyuoKBJTTlssRWwijVaVAm09sAbaBqrVSf2ZfiJ4AwLRKL9jfzg_bgDFxxX0a-DKl8Ke8Hrkn3kXsd5OfY9rwyzTkeRum6Cd-G3vMrx7n2E-BLvitx-eAxMeMfFlMmKkImIvOHz3tGchXgWJOxAv8riBDmom_xXnLuy3mVJy_QirsKx-nHYZTdjz6icLXj3nCHq4uf3c_qtXP65tuuap6ARYqFYQcfKMbY6WR_Rqa4JWVwrT1um_kutVr8EXXNbQWDAxSNXbQ2oqgh9EoecLEgVs2IsIwuleMLx7fnQC3b9YdmnWlWbdv1kHJ1IcMFW_aBHRPeYfl8_Tf0NkhNPrs_AYjuYf7GoQEYeu6Nlr-A3i2hhE</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Shehata, Mohammed</creator><creator>El Abd, Dina</creator><creator>El Shanawani, Faten</creator><creator>Abdallah, Emad Ali</creator><creator>Darwish, Hesham</creator><creator>Moghazy, Mahmoud Farok</creator><creator>Metwaly, Amna</creator><creator>Hadi, Afaf Ahmed Abdel</creator><general>New York : Springer-Verlag</general><general>Springer-Verlag</general><scope>FBQ</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2010</creationdate><title>Cadherin 5 and Annexin V as Circulating Endothelial Microparticles: Markers for Atherosclerotic Vascular Lesions in Patients with Chronic Renal Failure</title><author>Shehata, Mohammed ; El Abd, Dina ; El Shanawani, Faten ; Abdallah, Emad Ali ; Darwish, Hesham ; Moghazy, Mahmoud Farok ; Metwaly, Amna ; Hadi, Afaf Ahmed Abdel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1090-5e13da46489383cb04ea5931872bc43b76b0aa4662079080d3549d6691e6df853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Annexin V</topic><topic>Cadherin5</topic><topic>CKD</topic><topic>Endothelial dysfunction</topic><topic>Haemodialysis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>myocardial ischemia</topic><topic>Nephrology</topic><topic>Urology</topic><toplevel>online_resources</toplevel><creatorcontrib>Shehata, Mohammed</creatorcontrib><creatorcontrib>El Abd, Dina</creatorcontrib><creatorcontrib>El Shanawani, Faten</creatorcontrib><creatorcontrib>Abdallah, Emad Ali</creatorcontrib><creatorcontrib>Darwish, Hesham</creatorcontrib><creatorcontrib>Moghazy, Mahmoud Farok</creatorcontrib><creatorcontrib>Metwaly, Amna</creatorcontrib><creatorcontrib>Hadi, Afaf Ahmed Abdel</creatorcontrib><collection>AGRIS</collection><collection>CrossRef</collection><jtitle>Kidney (Springer International (Firm))</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shehata, Mohammed</au><au>El Abd, Dina</au><au>El Shanawani, Faten</au><au>Abdallah, Emad Ali</au><au>Darwish, Hesham</au><au>Moghazy, Mahmoud Farok</au><au>Metwaly, Amna</au><au>Hadi, Afaf Ahmed Abdel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cadherin 5 and Annexin V as Circulating Endothelial Microparticles: Markers for Atherosclerotic Vascular Lesions in Patients with Chronic Renal Failure</atitle><jtitle>Kidney (Springer International (Firm))</jtitle><stitle>Kidney</stitle><date>2010</date><risdate>2010</risdate><volume>19</volume><issue>6</issue><spage>307</spage><epage>315</epage><pages>307-315</pages><issn>0940-7936</issn><eissn>1865-5068</eissn><abstract>Cardiovascular disease is the leading cause of death in Chronic kidney disease patients. This study tries to identify circulating endothelial microparticles {MPs} [such as Cadherin 5 and Anexin V] in CKD patients with and without IHD as potential new risk factors of atherosclerotic vascular disease. This study was carried out in Theodor Bilharz Research Institute [TBRI] on 60 patients with chronic kidney disease on maintenance hemodialysis. They were 41 male and 19 females selected from hemodialysis unit in TBRI. They were further subclassified into the following two groups according to the Echocardiography and Electrocardiogram (ECG) to 25 patients of chronic kidney disease without cardiac complications (17 males, 8 females and ages were 53.5 ± 9.9 years) and 35 patients of chronic kidney disease with cardiac complications (24 males, 11 females and ages were 57.5 ± 7.4 years). Twenty healthy subjects were selected as healthy control, their age 50 ± 9 years. Cadherin 5 &amp; Annexin V Were done by enzyme linked immunosorbant assay (ELISA). The mean cadherin 5 levels in CKD with ischemic HD, CKD without ischemic HD and control group were 86.99 ± 21.51, 33.21 ± 8.65 and 2.63 ± 1.47 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p &lt; 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p &lt; 0.01). As regard to the mean annexin v levels in CKD with ischemic HD, CKD without ischemic HD and control group were 83.73 ± 22.64, 28.51 ± 9.73 and 0.47 ± 0.36 respectively which significantly higher in CKD with ischemic HD and CKD without ischemic HD than control group (p &lt; 0.01) and significantly higher in CKD with ischemic HD than CKD without ischemic HD (p &lt; 0.01). Endothelial dysfunction leading to atherosclerotic vascular disease in patients with CKD can be assessed quantitatively by measurement of plasma levels of endothelial microparticles such as CD144-EMP (Cadherin 5) and Annexin V.</abstract><cop>New York</cop><pub>New York : Springer-Verlag</pub><doi>10.1007/s00596-010-0176-0</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0940-7936
ispartof Kidney (Springer International (Firm)), 2010, Vol.19 (6), p.307-315
issn 0940-7936
1865-5068
language eng
recordid cdi_crossref_primary_10_1007_s00596_010_0176_0
source Alma/SFX Local Collection
subjects Annexin V
Cadherin5
CKD
Endothelial dysfunction
Haemodialysis
Medicine
Medicine & Public Health
myocardial ischemia
Nephrology
Urology
title Cadherin 5 and Annexin V as Circulating Endothelial Microparticles: Markers for Atherosclerotic Vascular Lesions in Patients with Chronic Renal Failure
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T22%3A16%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-fao_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cadherin%205%20and%20Annexin%20V%20as%20Circulating%20Endothelial%20Microparticles:%20Markers%20for%20Atherosclerotic%20Vascular%20Lesions%20in%20Patients%20with%20Chronic%20Renal%20Failure&rft.jtitle=Kidney%20(Springer%20International%20(Firm))&rft.au=Shehata,%20Mohammed&rft.date=2010&rft.volume=19&rft.issue=6&rft.spage=307&rft.epage=315&rft.pages=307-315&rft.issn=0940-7936&rft.eissn=1865-5068&rft_id=info:doi/10.1007/s00596-010-0176-0&rft_dat=%3Cfao_cross%3EUS201301922286%3C/fao_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1090-5e13da46489383cb04ea5931872bc43b76b0aa4662079080d3549d6691e6df853%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true